Related references
Note: Only part of the references are listed.Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia
Shakir Ahamad et al.
DRUG DISCOVERY TODAY (2022)
Chemical insights into flexizyme-mediated tRNA acylation
Jaime N. Coronado et al.
CELL CHEMICAL BIOLOGY (2022)
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
Thomas J. Tucker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
PCSK9-targeted therapies: present and future approaches
Mahmoud Al Rifai et al.
NATURE REVIEWS CARDIOLOGY (2021)
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Kiran Musunuru et al.
NATURE (2021)
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
Tanja Rothgangl et al.
NATURE BIOTECHNOLOGY (2021)
An oral antisense oligonucleotide for PCSK9 inhibition
Peter Gennemark et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Pre-Clinical Evaluation of the Nanoliposomal antiPCSK9 Vaccine in Healthy Non-Human Primates
Amir Abbas Momtazi-Borojeni et al.
VACCINES (2021)
Materials for oral delivery of proteins and peptides
Tyler D. Brown et al.
NATURE REVIEWS MATERIALS (2020)
EFFICACY AND SAFETY OF A 52 WEEK OPEN LABEL PHASE 2B EXTENSION TRIAL WITH MONTHLY DOSING OF AN ANTI-PCSK9 SMALL BINDING PROTEIN
Evan A. Stein et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design
Candice Alleyne et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Expanding the Chemical Diversity of Genetically Encoded Libraries
Sabrina E. Iskandar et al.
ACS COMBINATORIAL SCIENCE (2020)
Small molecules as inhibitors of PCSK9: Current status and future challenges
Shengtao Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial
Michael Szarek et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Small Molecule Inhibitors of the PCSK9 center dot LDLR Interaction
Jam Taechalertpaisarn et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Just Price for PCSK9 Inhibitors: No less, No More
Khurram Nasir
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Macrocycle peptides delineate locked-open inhibition mechanism for microorganism phosphoglycerate mutases
Hao Yu et al.
NATURE COMMUNICATIONS (2017)
Highly selective inhibition of histone demethylases by de novo macrocyclic peptides
Akane Kawamura et al.
NATURE COMMUNICATIONS (2017)
Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach
Sumathy Mathialagan et al.
DRUG METABOLISM AND DISPOSITION (2017)
Roles of Mas-related G protein-coupled receptor X2 on mast cell-mediated host defense, pseudoallergic drug reactions, and chronic inflammatory diseases
Hariharan Subramanian et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab
Marian McDonagh et al.
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY (2016)
Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions
Benjamin D. McNeil et al.
NATURE (2015)
Targeting PCSK9 for Hypercholesterolemia
Giuseppe Danilo Norata et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54 (2014)
PCSK9: A Key Modulator of Cardiovascular Health
Nabil G. Seidah et al.
CIRCULATION RESEARCH (2014)
PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
Thomas A. Lagace
CURRENT OPINION IN LIPIDOLOGY (2014)
In Vitro Selection of Highly Modified Cyclic Peptides That Act as Tight Binding Inhibitors
Yollete V. Guillen Schlippe et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2012)
Phage-encoded combinatorial chemical libraries based on bicyclic peptides
Christian Heinis et al.
NATURE CHEMICAL BIOLOGY (2009)
Share Paper
